APA

Genovese M. C., Greenwald M. W., Gutierrez-Ureña S. R., Cardiel M. H., Poiley J. E., Zubrzycka-Sienkiewicz A., Codding C. E., Wang A., He W., Amos R., Vinueza R., Wang X., Garg J. P. & Kivitz A. J. (2019). Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. : Rheumatology and therapy.

Chicago

Genovese Mark C, Greenwald Maria W, Gutierrez-Ureña Sergio R, Cardiel Mario H, Poiley Jeffrey E, Zubrzycka-Sienkiewicz Anna, Codding Christine E, Wang Annie, He Weizhong, Amos Rebecca, Vinueza Raul, Wang Xuegong, Garg Jay P and Kivitz Alan J. 2019. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. : Rheumatology and therapy.

Harvard

Genovese M. C., Greenwald M. W., Gutierrez-Ureña S. R., Cardiel M. H., Poiley J. E., Zubrzycka-Sienkiewicz A., Codding C. E., Wang A., He W., Amos R., Vinueza R., Wang X., Garg J. P. and Kivitz A. J. (2019). Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. : Rheumatology and therapy.

MLA

Genovese Mark C, Greenwald Maria W, Gutierrez-Ureña Sergio R, Cardiel Mario H, Poiley Jeffrey E, Zubrzycka-Sienkiewicz Anna, Codding Christine E, Wang Annie, He Weizhong, Amos Rebecca, Vinueza Raul, Wang Xuegong, Garg Jay P and Kivitz Alan J. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. : Rheumatology and therapy. 2019.